

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: TDM1/22 - Therapeutic Drugs

Deadline: 29.04.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability										Traceability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
Set 1																								
(81) Digoxin	[µg/L]				16							0									16	16	100%	
Samples and groups																								
Sample A1		2,19	0,19	8,6	16							0		CRV	2,15	0,020	36%	1,37	2,93	16	16	100%		
(4) LIA, ILMA		2,15	0,30	14	9	0														9				
(6) Immunoturbidimetry, KIMS		2,19	0,00	0,34	5	0														5				
Other					2	0														2				
-----													2x 2											
Sample B1		1,02	0,14	14	16							0		CRV	1,03	0,0100	36%	0,659	1,41	16	16	100%		
(4) LIA, ILMA		1,00	0,16	16	9	0														9				
(6) Immunoturbidimetry, KIMS		1,06	0,01	1,4	5	0														5				
Other					2	0														2				
-----													2x 2											
(84) Phenobarbital	[mg/L]				6							6	4	67%							0			
Samples and groups																								
Sample A1		9,07	0,85	9,4	6	CVP	8,99	0,47	20%	7,19	10,8	6	4	67%							0			
Other					6	0						6												
-----						4x 4, 2x 6																		
Sample B1		26,3	2,4	9,0	6	CVP	24,9	0,88	20%	19,9	29,9	6	5	83%							0			
Other					6	0						6												
-----						4x 4, 2x 6																		
(85) Phenytoin	[mg/L]				3							3	3	100%							0			
Samples and groups																								
Sample A1		4,13	0,32	7,8	3	CVP	3,91	0,13	20%	3,12	4,7	3	3	100%							0			
Other					3	0						3												
-----						1x 4, 2x 6																		
Sample B1		10,3	1,1	11	3	CVP	9,56	0,26	20%	7,64	11,5	3	3	100%							0			
Other					3	0						3												
-----						1x 4, 2x 6																		
(86) Carbamazepin	[mg/L]				12							12	10	83%							0			
Samples and groups																								
Sample A1		3,34	0,33	9,8	12	CVP	3,45	0,11	20%	2,76	4,14	12	11	92%							0			
Other					12	0						12												
-----						1x 1, 3x 2, 4x 4, 4x 6																		
Sample B1		9,30	0,96	10	12	CVP	10	0,26	20%	8	12	12	10	83%							0			
Other					12	0						12												
-----						1x 1, 3x 2, 4x 4, 4x 6																		
(88) Valproic acid	[mg/L]				13							13	12	92%							0			
Samples and groups																								
Sample A1		125	7,4	5,9	13	CVP	127	2,2	20%	101	153	13	13	100%							0			

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: TDM1/22 - Therapeutic Drugs

Deadline: 29.04.2022

Test	[unit]	Comparability										Traceability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(88) Valproic acid						13							13	12	92%								0	
Samples and groups	[mg/L]																							
Sample A1		125	7,4	5,9	13	CVP	127	2,2	20%	101	153	13	13	100%								0		
(6) Immunoturbidimetry, KIMS		125	2,6	2,1	6							6												
Other					7							7												
-----						1x 1, 2x 2, 4x 4																		
Sample B1		34,4	5,0	14	13	CVP	35,1	0,68	20%	28	42,2	13	12	92%								0		
(6) Immunoturbidimetry, KIMS		35,9	3,6	9,9	6							6												
Other					7							7												
-----						1x 1, 2x 2, 4x 4																		
(82) Theophylline						4																4	3	75%
Samples and groups	[mg/L]																							
Sample A1		17,2	5,0	29	4							0		CRV	18,39	0,18	24%	13,9	22,9		4	3	75%	
Other					4	0																4		
-----														1x 2, 2x 4, 1x 6										
Sample B1		21,2	6,8	32	4							0		CRV	22,58	0,23	24%	17,1	28		4	3	75%	
Other					4	0																4		
-----														1x 2, 2x 4, 1x 6										
Set 2																								
(89) Amicacin						4							4	3	75%								0	
Samples and groups	[mg/L]																							
Sample A2		29,9	14	46	4	CVP	35,6	1,2	20%	28,4	42,8	4	3	75%								0		
Other					4	0						4												
-----						3x 2, 1x 6																		
Sample B2		8,27	2,3	28	4	CVP	9,5	0,30	20%	7,6	11,4	4	3	75%								0		
Other					4	0						4												
-----						3x 2, 1x 6																		
(90) Gentamicin						11							11	11	100%								0	
Samples and groups	[mg/L]																							
Sample A2		9,41	1,1	12	11							11	11	100%									0	
Other					11	0						11												
-----						1x 1, 2x 2, 4x 4, 3x 6, 1x 6/60																		
Sample B2		7,19	0,98	14	11							11	11	100%									0	
Other					11	0						11												
-----						1x 1, 2x 2, 4x 4, 3x 6, 1x 6/60																		
(93) Methotrexate						3							3	2	67%								0	
Samples and groups	[µmol/L]																							
Sample A2		1,97	0,43	22	3	CVP	2,18	0,20	30%	1,52	2,84	3	2	67%								0		
Other					3	0						3												
-----						1x 2, 2x 4																		
Sample B2		0,977	0,21	22	3	CVP	1,2	0,11	30%	0,84	1,56	3	2	67%								0		
Other					3	0						3												
-----						1x 2, 2x 4																		
(92) Vankomycin						13							13	13	100%								0	
Samples and groups	[mg/L]																							
Sample A2		14,5	1,2	8,4	13	CVP	14,1	0,40	28%	10,1	18,1	13	13	100%								0		
(4) LIA, ILMA		15,2	0,96	6,4	6	0						6												

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: TDM1/22 - Therapeutic Drugs

Deadline: 29.04.2022

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(92) Vankomycin					13							13	13	100%									0
Samples and groups	[mg/L]																						
Sample A2		14,5	1,2	8,4	13	CVP	14,1	0,40	28%	10,1	18,1	13	13	100%								0	
Other					7							7											
						1x 1, 2x 2, 4x 6																	
Sample B2		16,6	1,5	8,9	13	CVP	16,4	0,49	28%	11,8	21	13	13	100%								0	
(4) LIA, ILMA		17,2	1,3	7,8	6							6											
Other					7							7											
						1x 1, 2x 2, 4x 6																	

st_kn_np

End of report

Printed: 07.05.2022